<VariationArchive VariationID="3068856" VariationName="NC_000006.11:g.(49425772_49426794)_(49430967_?)del" VariationType="Deletion" Accession="VCV003068856" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-20" DateCreated="2024-04-15" MostRecentSubmission="2024-04-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3228181" VariationID="3068856">
      <GeneList>
        <Gene Symbol="MMUT" FullName="methylmalonyl-CoA mutase" GeneID="4594" HGNC_ID="HGNC:7526" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>6p12.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="49430360" stop="49463253" display_start="49430360" display_stop="49463253" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="49398072" stop="49431040" display_start="49398072" display_stop="49431040" Strand="-" />
          </Location>
          <OMIM>609058</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000006.11:g.(49425772_49426794)_(49430967_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6p12.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" outerStart="49425772" innerStart="49426794" innerStop="49430967" display_start="49425772" display_stop="49430967" variantLength="5196" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.(49425772_49426794)_(49430967_?)del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.(49425772_49426794)_(49430967_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000006.11:g.(49425772_49426794)_(49430967_?)del AND Methylmalonic acidemia" Accession="RCV003994916" Version="1">
        <ClassifiedConditionList TraitSetID="9017">
          <ClassifiedCondition DB="MedGen" ID="C0268583">Methylmalonic acidemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-04-15" MostRecentSubmission="2024-04-15">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="9017" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6374" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
                <XRef ID="Methylmalonic+acidemia/4713" DB="Genetic Alliance" />
                <XRef ID="HP:0002912" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0002012" DB="MONDO" />
                <XRef ID="42393006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Isolated Methylmalonic Acidemia</ElementValue>
                <XRef ID="C537358" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MMA</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mut– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7033" />
                <XRef ID="7033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <XRef ID="C0268583" DB="MedGen" />
              <XRef ID="C537358" DB="MeSH" />
              <XRef ID="MONDO:0002012" DB="MONDO" />
              <XRef Type="primary" ID="HP:0002912" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0003123" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0008295" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8998120" SubmissionDate="2024-04-03" DateLastUpdated="2024-04-15" DateCreated="2024-04-15">
        <ClinVarSubmissionID localKey="NC_000006.11:g.(49425772_49426794)_(49430967_?)del|MedGen:C0268583" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004813525" DateUpdated="2024-04-15" DateCreated="2024-04-15" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant summary: The variant involves the deletion of exons 1-2 in the MUT gene. A presumed nomenclature of c.(?_-191)_(385+1_386-1)del has been designated for the purposes of this classification. The exact breakpoint at the 5' end of this variant is unknown, therefore this deletion may extend upstream of the annotated region of this gene. Although the exact breakpoints of this deletion are not known, it is predicted to remove the initiation codon and result in an absence of protein or a truncation of the encoded protein due to translation initiation at a downstream site. The variant was absent in 123,614 control chromosomes in the gnomAD database (Structural Variants v4.0 dataset). To our knowledge, no occurrence of c.(?_-191)_(385+1_386-1)del in individuals affected with Methylmalonic Acidemia and no experimental evidence demonstrating its impact on protein function have been reported. No submitters have cited clinical-significance assessments for this variant to ClinVar. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMUT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.(49425772_49426794)_(49430967_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268583" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14342304</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8998120" TraitType="Disease" MappingType="XRef" MappingValue="C0268583" MappingRef="MedGen">
        <MedGen CUI="C0268583" Name="Methylmalonic acidemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

